administration, especially in the form of tablets, dragees, capsules, solutions, liquids, gels, plaster, creams, ointments, syrup, slurries, suspensions, spray, nebulizer or suppositories.

13. A compound of formula (I) according to any one of claims 1 to 10, or a pharmaceutically acceptable salt thereof, for use as a medicament.

14. The use of a compound according to any one of claims 1 to 10 as a pharmaceutically active substance having antagonistic activity against the FPR1 receptor.

~~15. The use of a compound according to any one of claims 1 to 10, or a composition~~ according claim 11 or 12, for the treatment or prevention of diseases or conditions in the areas of inflammatory diseases, allergic conditions, immunological disorders, neuroinflammation, neurological disorders, pain, prion-mediated diseases, amyloid-mediated diseases, obstructive airway diseases, infectious diseases, cardiovascular ~~disorders, and proliferative disorders such as cancer.~~

16. A process for the preparation of a compound according to any one of claims 1 to 10 which comprises

(a) coupling an appropriately functionalized solid support with an appropriately N-protected derivative of that amino acid which in the desired end-product is in position T^1 or T^2 or P^1 to P^{14} as defined above; any functional group which may be present in said N-protected amino acid derivative being likewise appropriately protected;

(b) removing the N-protecting group from the product obtained in step (a);

(c) coupling the product thus obtained with an appropriately N-protected derivative of that amino acid which in the desired end-product is in the position of the next element (T or P), following counterclockwise or clockwise the sequence according to general formula (I) in –COOH to $–NH_2$ orientation; any

functional group which may be present in said N-protected amino acid derivative being likewise appropriately protected;

(d) removing the N-protecting group from the product thus obtained;

(e) repeating steps (c) and (d) until all amino acid residues have been introduced;

(f) if desired, selectively deprotecting one or several protected functional group(s) present in the molecule and chemically transforming the reactive group(s) thus liberated;

(g) detaching the product thus obtained from the solid support;

(h) cyclizing the product cleaved from the solid support;

(i) removing any protecting groups present on functional groups of any members of the chain of amino acid residues and, if desired, any protecting group(s) which may in addition be present in the molecule;

(j) if desired, forming a disulfide bridge between the sulfhydryl containing residues at P^4 and P^{11};

(k) if desired, implementing additional chemical transformations of one or more reactive group(s) present in the molecule; and

(l) if desired, converting the product thus obtained into a pharmaceutically acceptable salt or converting a pharmaceutically acceptable, or unacceptable, salt thus obtained into the corresponding free compound of formula **(I)** or into a different, pharmaceutically acceptable salt.

17. The use of a compound according to any one of claims 1 to 10 for the manufacture of a medicament to treat or prevent diseases or conditions in the areas of inflammatory diseases, allergic conditions, immunological disorders, neuro-inflammation, neurological disorders, pain, prion-mediated diseases, amyloid-mediated diseases, obstructive airway diseases, infectious diseases, cardiovascular disorders, and proliferative disorders such as cancer.

~~18. A method of treating a disease or disorder associated with the FPR1 receptor,~~ especially such as acute and chronic lung inflammation, COPD, asthma, emphysema,

inflammation of the gastrointestinal tract, inflammatory bowel disease (IBD), Crohn's disease, acute skin inflammation, atopic dermatitis, eczema, psoriasis, rosacea, acne, neutrophilic dermatosis, neutrophil disorder, eosinophil disorder, monocyte/macrophage associated diseases, Jobs syndrome, Chédiak-Higashi syndrome, chronic granulomatous disease, leukocyte adhesion deficiency, cystic fibrosis, peritonitis, periodontitis, sepsis, pneumonia, bacterial infection, and proliferative disorders such as cancer, comprising administering to a subject in need thereof a pharmaceutically acceptable amount of a compound or pharmaceutical composition according to any one of claims 1 to 12.